Wave Life Sciences to Present New Data on Its DMD Exon 53 Skipping Program and Discovery Platform at Upcoming Meetings
23rd International Annual Congress of the
A poster entitled “Identification of Potent, Muscle-Targeting Investigational Stereopure Oligonucleotides for Exon 53 DMD Therapy” (Poster #127) will be presented on
WVE-210201 is currently being studied in a global Phase 1 clinical trial in DMD patients amenable to exon 51 skipping. As patients complete the Phase 1 trial, they have the option to enroll in an ongoing open-label extension study in which they continue to receive WVE-210201.
14th Annual Meeting of the
A presentation entitled “Stereochemical Control of Antisense Oligonucleotides Enhances Target Efficacy” will take place on
Wave will also present the following three posters at this meeting:
- “Optimized, Stereopure Antisense Oligonucleotides Achieve Broad Tissue Distribution and Excellent Exposure, Enabling Potent and Durable Knockdown of Nuclear Malat1 in Mice and Nonhuman Primates” (Poster #030)
- “A Bicyclic Synthetic Ligand for ASGR is a Safe Alternative to GalNAc for Effective Hepatocyte-specific Delivery in Mouse Models” (Poster #092)
- “Cellular Free-Uptake Models for Optimized, Stereopure Antisense Oligonucleotides Predict Exon Skipping Efficiency and Dystrophin Protein Restoration in Mice” (Poster #119)
Data from the presentation and the three posters highlight advances in Wave’s novel chemistry platform and its ability to precisely design, optimize and manufacture stereopure oligonucleotides.
About Wave Life Sciences
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the potential for Wave’s preclinical data, including data from Wave’s exon 23 skipping oligonucleotide in the mdx 23 mouse model, to predict the behavior of Wave’s compounds, including its exon 53 skipping program, in humans; Wave’s ability to leverage the learnings from its ongoing neuromuscular research to apply to its new neuromuscular compounds; the potential of Wave’s DMD programs to help boys suffering from DMD; the future performance and results of Wave’s DMD compounds in clinical trials. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the
Investor Contact:
781-686-9600
gmorrell@wavelifesci.com
Media Contact:
José Juves
617-949-4708
jjuves@wavelifesci.com
Patient Contact:
617-949-2898
werler@wavelifesci.com
Source: Wave Life Sciences